Detailed Instructions: In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
Q: Tweet with a location 
  
 You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications. You always have the option to delete your Tweet location history. Learn more ||||| Pfizer previously said the rollback would give Trump an opportunity to work on his administration's drug price plan. | Mario Tama/Getty Images Pfizer raises drug prices again, rebuking Trump 
  
 Drug giant Pfizer announced on Friday it will increase the list prices of 41 medicines in January, just months after it agreed to temporarily roll back price hikes under pressure from President Donald Trump. 
  
 Pfizer's new price increases, which take effect Jan. 15, will apply to 10 percent of its portfolio, the company said. Most of those drugs will see 5 percent increases. 
  
 Story Continued Below 
  
 Trump attacked Pfizer in July after the company raised prices, just weeks after he announced a drug pricing plan he claimed would result in "historic" price cuts. Trump accused the company of "taking advantage of the poor & others unable to defend themselves," and Pfizer a day later agreed to cancel the price increases. 
  
 Pfizer at the time said the rollback would give Trump an opportunity to work on his administration's drug price plan. The company said it would reinstate price increases at the end of the year if the administration's drug pricing plan didn't take effect. 
  
 A spokesperson for HHS Secretary Alex Azar criticized Pfizer’s latest price hikes, saying they “further illustrate the perverse incentives of America’s drug pricing system.” 
  
 Prescription Pulse A weekly briefing on pharmaceutical policy news — in your inbox. Email Sign Up By signing up you agree to receive email newsletters or alerts from POLITICO. You can unsubscribe at any time. 
  
 Trump's criticism of Pfizer earlier this year also prompted nine other drugmakers to roll back or freeze prices. But the gestures were largely seen as symbolic, with some companies agreeing to freeze prices just weeks after they already took what is usually their last price increases of the year — companies typically raise prices in January and July. Health policy experts have expected the industry would resume regular price increases starting in January. 
  
 “The drug price pledges made earlier this year were just for show — it was obvious at the time, and it's obvious now,” said Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. “The bully pulpit doesn't work, and even if it did, we don't want a system in which the only way to bring down drug prices is for the president to publicly berate a company — that's not a healthy market and not good policy.” 
  
 But some health policy experts said they think Trump’s tendency to lash out at drug companies will keep price hikes lower next year, even it doesn’t completely eliminate them. 
  
 “I think it’s less likely we’ll see the same manner of price increases of previous years (double digit) that the market had grown accustomed to, but I don’t think that entails a wholesale stop to price increases,” John Leppard, an analyst at the research firm Washington Analysis, said in an email. 
  
 Pfizer said the new price increases are expected to be offset by higher rebates and discounts given to insurance companies and pharmacy benefits managers, and it doesn’t expect the hikes will increase its 2019 revenue. Azar spokesperson Caitlin Oakley pointed out the company’s discounts won’t help consumers who must pay list price or a set percentage of it. 
  
 Trump's drug pricing plan from May, a 44-page outline of proposals, largely remains unimplemented. Drug pricing is one area where the new Democratic House majority could find common ground with Trump. 
  
 Some Wall Street analysts said drug companies were holding down price increases this summer to avoid provoking more aggressive action from the Trump administration. But just before the elections, the administration offered proposals the industry doesn't like, including one tying Medicare payments for some expensive drugs to lower prices set by European countries. 
  
 Drug companies, "don't need to play nice anymore (or not 'as nice')," Bernstein investment analyst Ronny Gal said in an email. 
  
  ||||| These two "quality" stocks look like a buy in a volatile market 2:35 PM ET Mon, 12 Nov 2018 | 03:24 
  
 List prices are the advertised price of a drug, not necessarily the price insurers pay after discounts, known as rebates. 
  
 The news was first reported by the Wall Street Journal. 
  
 "We believe the best means to address affordability of medicines is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance, and ensure that patients receive the benefit of rebates at the pharmacy counter," Pfizer's outgoing CEO Ian Read said in a statement. 
  
 Trump criticized Pfizer this summer when the company said it would raise prices on about 40 drugs. He tweeted that Pfizer and other drugmakers "should be ashamed" for increasing drug prices. 
  
 Pfizer reversed course and said it would hold off on making these increases until the end of the year or until Trump's blueprint to lower drug prices went into effect. On an earnings call with Wall Street analysts last month, Read said by the end of the year, the company's strategy on price increases would be back to "business as normal." ||||| Pfizer Inc, which is planning a merger of $160 billion with Allergen based in Ireland to cut its annual tax bill, raised the prices in the U.S. on January 1 of over 100 drugs, of which some were hiked by 20%, according to a global information company online that compiled the statistics. 
  
 Pfizer confirmed an increase of 9.4% for Lyrica its pain drug that is heavily advertised, which generated over $2.3 billion in U.S. sales during 2014; an increase of 12.9% for Viagra its erectile dysfunction pill, which has sales in the U.S. during 2014 of $1.1 billion; and an increase of 5% in Ibrance, a drug for breast cancer launched in 2015 at an annual price of $118,200. 
  
 A spokesperson for the company said he could not confirm the price increases, which had been compiled by the statistical company. 
  
 Lawmakers in the U.S. and candidates for president have recently stepped up their criticism of drug prices in the U.S. driven partly by the price hikes of incredible proportion from companies that recently acquired the rights to generic drugs. 
  
 Medicines are amongst the most efficient and effective use of public and private healthcare dollars said Pfizer in a statement that was emailed. 
  
 Pfizer, said an industry analyst, increased prices by up to 20% for Menest its hormone therapy, Dilantin its anticonvulsant, Nitrostat for angina, Tykosyn for a heartbeat that is irregular and Tygacil an antibiotic. 
  
 The report by the analyst said prices in the U.S. were increased on 105 drugs at Pfizer, with no reported prices reductions. 
  
 Pfizer by no means is the only drug makers that increased its prices. On online research firm found that prices of prescription drugs in the U.S. were increased 10.9% during 2014, including by 15% for products that were brand name. 
  
 The planned deal between Pfizer and Allergen would create the largest drug maker in the world and shift the headquarters of Pfizer to Ireland. It would also be the one instance that was the biggest ever of a company in the U.S. re-incorporating overseas as a way to lower its own taxes. |||||
A:
Give it to Pfizer—they waited a while. The pharmaceutical giant is raising the price of 41 prescription drugs after hitting the pause button this summer when President Trump opposed a price hike, reports CNBC. Most prices are slated to rise 5%, while Stocks Beat says the pain drug Lyrica will go up 9% and Viagra nearly 13%. These are advertised prices, which may differ from what insurers fork out after discounts. "We believe the best means to address affordability of medicines is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance, and ensure that patients receive the benefit of rebates at the pharmacy counter," says outgoing Pfizer CEO Ian Read. About 10% of Pfizer's drug prices are slated to rise. Pfizer initially rolled out a price-hike plan in July and ran headlong into a Trump tweet: "Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves. ... We will respond!" Pfizer quickly backtracked, saying it shared "the President's concern for patients" and would hold off until Trump enacted a plan to curb drug prices, or the year ended—whichever came first, per the Wall Street Journal. Trump has announced a plan, and Pfizer's hike is slated for Jan. 15. Mostly unimplemented, Trump's plan is one thing he and Democrats may just agree on, notes Politico. (A $96 billion deal may reshape health care as we know it.)